Illumina has appointed Paul Grint to its board of directors. Grint is currently senior vice president and chief medical officer of Zephyr Sciences, a biopharmaceutical company. He received his MD from the University of London, St. Bartholomew's Hospital Medical College.
Illumina also announced the April 12 resignation of director Scott Greer, chairman of Abgenics, an Illumina director since May 2001.
Galapagos has appointed Andre Hoekema as managing director of Galadeno, Galapagos' services unit. Galadeno performs target discovery using adenoviral siRNA technologies.
Hoekema, 47, joins Galapagos from Invitrogen, where he served as the managing director of corporate development in Europe.
Ambrx has appointed Bruce Kimmel as vice president of therapeutic applications. He obtained his PhD in biochemistry from the University of California, Berkeley, and conducted postdoctoral work at UCSF.
Stratagene has hired David Weber as its new senior vice president of marketing. He comes to Stratagene from GE Healthcare, where he was president, Region Americas, where he managed sales for the United States, Canada, and Latin America. Weber earned a BS in biochemistry from Rutgers University.